Key result
Targeting beta-3 adrenergic receptors represents a novel potential strategy to improve cardiac metabolism, function, and remodeling in heart failure.
Why the study?
Does targeting beta3-adrenergic receptors improve cardiac metabolism, function, and remodeling in heart failure?
Does targeting beta3-adrenergic receptors improve cardiac metabolism, function, and remodeling in heart failure?
Targeting beta3-adrenergic receptors represents a novel potential strategy to improve cardiac function and remodeling in heart failure, potentially mediating some of the cardioprotective effects of certain beta-blockers.
Should not alter current HF management; leaves open beta-3 targeting for prospective validation.
Cardiac diseases, such as heart failure, remain leading causes of morbidity and mortality worldwide, with myocardial infarction as the most common etiology. HF is characterized by β-adrenergic receptor (βAR) dysregulation that is primarily due to the upregulation of G protein-coupled receptor kinases that leads to overdesensitization of β1 and β2ARs, and this clinically manifests as a loss of inotropic reserve. Interestingly, the "minor" βAR isoform, the β3AR, found in the heart, lacks G protein-coupled receptor kinases recognition sites, and is not subject to desensitization, and as a consequence of this, in human failing myocardium, the levels of this receptor remain unchanged or are even increased. In different preclinical studies, it has been shown that β3ARs can activate different signaling pathways that can protect the heart. The clinical relevance of this is also supported by the effects of β-blockers which are well known for their proangiogenic and cardioprotective effects, and data are emerging showing that these are mediated, at least in part, by enhancement of β3AR activity. In this regard, targeting of β3ARs could represent a novel potential strategy to improve cardiac metabolism, function, and remodeling.
No takes yet. Share an insight, caveat, or question.
Cannavò et al. (2016) conducted a review in Heart failure. Beta-3 adrenergic receptor agonists and beta-blockers was evaluated. Targeting beta-3 adrenergic receptors represents a novel potential strategy to improve cardiac metabolism, function, and remodeling in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: